Methods of treating gastrointestinal diseases and disorders
Rectal administration of a single daily dose of hydrocortisone acetate suppository effectively treats ulcerative colitis by achieving clinical remission and symptom reduction with lower systemic absorption and adverse events, addressing the need for safer and more effective treatments.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-12-22
- Publication Date
- 2026-07-09
AI Technical Summary
There is a need for safer and more effective hydrocortisone suppository formulations for treating gastrointestinal diseases and disorders such as ulcerative colitis and Crohn's disease.
A method involving the rectal administration of a single suppository containing hydrocortisone or its salt, preferably hydrocortisone acetate, once a day in the morning, with a dosage of about 90 mg, followed by a tapering period of reduced dosage, to achieve remission or reduction of symptoms.
The method achieves clinical remission and reduces symptoms of ulcerative colitis by maintaining effective cortisol levels, minimizing systemic absorption, and reducing adverse events, with improved pharmacokinetics and safety profiles compared to twice-daily administration.
Smart Images
Figure US2025060884_09072026_PF_FP_ABST